Prevention of diabetes: Effect of mycophenolate mofetil and anti-CD25 on onset of diabetes in the DRBB rat

Pediatric Diabetes

Volumn 9, Issue 6, 2008, Pages 596-601

  Ugrasbul, Figen ^a   Moore, Wayne V ^a   Tong, Pei Ying ^a   Kover, Karen L ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti CD25; Autoimmune diabetes; DRBB rat; MMF; Prevention

Indexed keywords

BASILIXIMAB; GLUCOSE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DIABETES; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; EXPERIMENTAL DIABETES MELLITUS; EXPERIMENTAL RAT; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; T CELL DEPLETION;

ANIMALS; ANTIBODIES; DIABETES MELLITUS, TYPE 1; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MYCOPHENOLIC ACID; PANCREAS; RATS; RATS, INBRED BB;

EID: 56849107104     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2008.00417.x     Document Type: Article

References (28)

1. Sollinger HW. Mycophenolates in transplantation. Clin Transplant 2004: 18: 485-492.
2. Zandman-Goddard G, Shoenfeld Y. Mycophenolate mofetil in animals models of autoimmune disease. Lupus 2005: 14 (Suppl. 1): S12-S16.
3. Appel GB, Radhakrishnan J, Ginzler EM. Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation 2005: 80 (Suppl. 2): S265-S271.
4. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000: 47: 85-118.
5. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 2005: 14 (Suppl. 1): S2-S8.
6. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005: 80 (Suppl. 2): S181-S190.
7. Hao L, Chan SM, Lafferty KJ. Mycophenolate mofetil can prevent the development of diabetes in BB rats. Ann NY Acad Sci 1994: 696: 328-332.
8. Maksimovic-Ivanic D, Trajkovic V, Miljkovic DJ, Stojkovic MM, Stosic-Grujicic S. Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil. Clin Exp Immunol 2002: 129: 214-223.
9. Smith KA. Interleukin-2: Inception, impact, and implications. Science 1988: 240: 1169-1176.
10. Church AC. Clinical advances in therapies targeting the interleukin-2 receptor. Q J Med 2003: 96: 91-102.
11. Strom TB, Kelley VE. Toward more selective therapies to block undesired immune responses. Kidney Int 1989: 35: 1026-1033.
12. Baan CC, van Gelder T, Balk AH et al. Functional responses of T cells blocked by anti-CD25 antibody therapy during cardiac rejection. Transplantation 2000: 69: 331-336.
13. Abramowicz D, Vanrenterghem Y, Squifflet JP et al. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: A multicenter prospective, pilot trial. Clin Transplant 2005: 19: 475-482.
14. Figueras J, Prieto M, Bernardos A et al. Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts. Transpl Int 2006: 19: 641-648.
15. Ekberg H, Grinyo J, Nashan B et al. Cyclosporin sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 2007: 7: 560-570.
16. Kover K, Geng Z, Hess DM, Benjamin CD, Moore WV. Anti-CD154 (CD40L) prevents recurrence of diabetes in islet isografts in the DR-BB rat. Diabetes 2000: 49: 1666-1670.
17. Greiner DL, Mordes JP, Handler ES, Angelillo M, Nakamura N, Rossini AA. Depletion of RT6.1+ T lymphocytes induces diabetes in resistant biobreeding/Worcester (BB/W) rats. J Exp Med 1987: 166: 461-475.
18. Winter WE, Schatz D. Prevention strategies for type 1 diabetes mellitus: current status and future directions. BioDrugs 2003: 17: 39-64.
19. Popovic J, Kover K, Moore WV. The effect of immunomodulators on prevention of autoimmune diabetes is stage dependent: FTY720 prevents diabetes at three different stages in the DRBB rat. Pediatr Diabetes 2004: 5: 3-9.
20. Berney T, Buhler LH, Majno P, Mentha G, Morel P. Immunosuppression for pancreatic islet transplantation. Transplant Proc 2004: 36 (Suppl. 2): 362S-366S.
21. Vantyghem MC, Marcelli-Tourvielle S, Pattou F, Noël C. Effects of non-steroid immunosuppressive drugs on insulin secretion in transplantation. Ann Endocrinol (Paris) 2007: 68: 21-27.
22. Froud T, Baidal DA, Ponte G, Ferreira JV, Ricordi C, Alejandro R. Resolution of neurotoxicity and beta-cell toxicity in an islet transplant recipient following substitution of tacrolimus with MMF. Cell Transplant 2006: 15: 613-620.
23. Polastri L, Galbiati F, Bertuzzi F et al. Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells. Acta Diabetol 2002: 39: 229-233.
24. Shapiro AM, Lakey JR, Ryan EA et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000: 343: 230-238.
25. Kuttler B, Kauert C, Wanka H, Diamantstein T, Han HJ. Temporary anti-CD25/CsA therapy induces CD4+ T-cell-mediated tolerance in BB/OK rats. J Autoimmun 1996: 9: 321-329.
26. Hahn HJ, Lucke S, Klöting I, Volk HD, Baehr RV, Diamantstein T. Curing BB rats of freshly manifested diabetes by short-term treatment with a combination of a monoclonal anti-interleukin 2 receptor antibody and a subtherapeutic dose of cyclosporin A. Eur J Immunol 1987: 17: 1075-1078.
27. Kuypers DR, Evenepoel P, Maes B, Coosenmans W, Pirenne J, Vanrenterghem Y. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003: 17: 234-241.
28. Moore WV, Chu W, Tong PY et al. Prevention of autoimmune diabetes in the DRBB rat by CD40/154 blockade. J Autoimmun 2002: 19: 139-145.